Table 1.
Patient demographics and stem cell collection characteristics
| Characteristic | % (n), N = 393 | |
|---|---|---|
| Age at ASCT, median, years (range) | 58 (25–73) | |
| Male | 63 (246) | |
| Race | Hispanic or Latino | 14 (55) |
| Asian | 11 (45) | |
| Black | 6 (25) | |
| Other | 1 (4) | |
| Pacific Islander | 1 (3) | |
| Unknown | 17 (66) | |
| White | 64 (250) | |
| ISS stage | 1 | 34 (133) |
| 2 | 22 (85) | |
| 3 | 18 (69) | |
| N/A | 27 (106) | |
| High-risk cytogenetics1 (N/A in n = 45) | 15 (60) | |
| Lines of chemotherapy before first ASCT | 1 | 49 (194) |
| 2 | 32 (125) | |
| 3 | 11 (42) | |
| >3 | 8 (32) | |
| Induction regimen | Doublet | 39 (154) |
| Triplet | 55 (216) | |
| Quadruplet | 2 (6) | |
| Other | 4 (17) | |
| Maintenance | Yes | 28 (110) |
| No | 72 (283) | |
| Mobilization method | Cyclophosphamide | 40 (159) |
| Cyclophosphamide + etoposide | 57 (225) | |
| G-CSF-based | 2 (8) | |
| D-PACE | 0.3 (1) | |
| Relapse after first ASCT | 61 (240) | |
| Median (range) | ||
| Number of apheresis sessions | 2 (1–8) | |
| Total CD34+ cells collected (x106 cells/kg) | 18.2 (3.4–112.4) | |
| CD34+ cells used in first ASCT (x106 cells/kg) | 5.7 (1.8–41.9) | |
| CD34+ cells remaining after first ASCT (x106 cells/kg) | 10.1 (1.5–104.5) | |
Table Abbreviations: ISS = International Staging System; ASCT = autologous stem cell transplant; G-CSF = granulocyte colony-stimulating factor; D-PACE = dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide
1
High-risk cytogenetics were defined as deletion 17p/monosomy 17, t(4;14), t(14;16), t(14;20), or gain 1q